What Церекард Treats: Main Uses and Benefits

The compound is relevant for the supportive management of various conditions related to cellular stress and compromised circulation.

The substance contributes to easing the overall burden of symptoms that create noticeable physiological strain. This includes diminished memory, reduced attention, and persistent mental fatigue (asthenia), which may interfere with daily functioning. The compound is also applied when appropriate to address psycho-emotional state disorders and vegetative symptoms like anxiety and emotional lability.

The primary therapeutic focus is on conditions such as recovery after an ischemic stroke and the management of chronic cerebral ischemia (dyscirculatory encephalopathy). In specialized clinical settings, it may be part of symptomatic management for alcohol withdrawal syndrome, acute poisoning by neurotropic substances, and is used in the complex therapy for primary open-angle glaucoma and chronic heart failure. The substance is applied in clinical settings where supportive symptom management is appropriate, particularly when mental or physical fatigue is pronounced.

“This approach supports general well-being during symptomatic phases by assisting with maintaining functional stability.”

---

Quick Fact: Relief for Asthenic Fatigue
Symptom focus: Helps manage persistent mental fatigue, reduced attention, and weakness.
Use context: Applied in scenarios where additional management of discomfort is required due to neuro-asthenic strain.

---

Eligibility Map: Who Can and Cannot Use Церекард — Official Regulatory Information

The eligibility for Церекард (Ethylmethylhydroxypyridine Succinate) is strictly defined by regulatory documents, which establish absolute contraindications for several population groups.

---

Eligibility Scope

Category	Official Regulatory Status
Populations for whom use is allowed	Adult patients (18 years and older) for approved conditions.
Populations for whom use is contraindicated	Patients with known hypersensitivity to the active ingredient or excipients.

---

Eligibility Classifications (High-Level)

Category	Regulatory Status
Conditions Prohibiting Use	Contraindicated in acute hepatic failure or acute renal failure (acute liver and/or kidney dysfunction).
Age-Related Rules	Contraindicated for children and adolescents under 18 years old; safety and efficacy are officially not established.
Physiological Status	Contraindicated during both pregnancy and lactation (breastfeeding) due to insufficient safety data.

---

Resulting Eligibility Structure

Official eligibility statements:

• Use is contraindicated in patients with a known hypersensitivity or any component of the medicine.
• The drug is contraindicated in cases of acute liver and/or kidney dysfunction.
• The use is contraindicated in individuals under 18 years old, during pregnancy, and during lactation.

Connection to the overall eligibility profile: Regulatory documents define who can and cannot use the medicine primarily through a list of absolute contraindications. Non-eligibility is established for specific life stages and physiological states where safety is not established, as well as for acute organ failure and hypersensitivity reactions. The standard population for whom use is permitted is defined as adult patients (18 years and older).

The official regulatory documentation for Церекард (Ethylmethylhydroxypyridine Succinate) details specific interactions primarily based on pharmacodynamic potentiation with other central nervous system (CNS) agents. The prescribing information establishes an additive effect when the medicine is co-administered with certain drug classes, meaning the overall effect of the interacting medicine may be enhanced.

Interaction Type	Interacting Agent	Official Regulatory Statement
Drug-Drug	Benzodiazepine Anxiolytics	Effects are enhanced (Additive Potentiation).
Drug-Drug	Anticonvulsants (e.g., Carbamazepine)	Effects are enhanced (Additive Potentiation).
Drug-Drug	Antiparkinsonian Agents (e.g., Levodopa)	Effects are enhanced (Additive Potentiation).
Drug-Substance	Ethyl Alcohol	Reduces the toxic effects of the substance.

Official regulatory sources also state that the medicine may enhance the effects of other Antidepressants and Neuroleptics. The overall interaction profile is defined by these additive effects on the CNS, as well as the specific documented interaction with ethyl alcohol. The official labeling does not classify any drug combinations as formally contraindicated due to interaction risk. Furthermore, the label contains no documentation of metabolic (CYP enzyme) or transporter-mediated interactions that would modify the exposure or concentration (AUC/Cmax) of co-administered agents. The official documents also do not specify any mandatory requirements for timing separation between doses.

The mechanism of Церекард (Ethylmethylhydroxypyridine Succinate, EMHPS) is multimodal, driven by the synergistic action of its two functional components, which simultaneously engages pathways for structural integrity and metabolic maintenance.

Церекард's succinate ion component acts as a metabolic substrate, feeding directly into the Mitochondrial Respiratory Chain Complex II. This action bypasses steps that require oxygen, which facilitates the continuity of ATP synthesis and cellular energy status under conditions of metabolic strain.

Simultaneously, the 3-hydroxypyridine moiety provides a dual layer of action: it functions as a direct scavenger of damaging free radicals and operates as a structural modulator by embedding itself in the cell membrane lipid bilayer. This stabilizes the lipid bilayer architecture, which decreases the susceptibility of membrane lipids to degradation (lipid peroxidation), thereby modulating cellular response to physical and chemical stress.

The drug's molecule also acts in the central nervous system (CNS) as an allosteric modulator of the inhibitory GABA-A receptor complex. By influencing the function of this key receptor, Церекард helps adjust the balance of inhibitory and excitatory signals, contributing to the modulation of neuronal excitability and influencing the dynamics of nerve cell communication.

How to Use Церекард

Церекард (Ethylmethylhydroxypyridine Succinate) is administered through a sequential therapeutic protocol, typically beginning with an injectable form and transitioning to an oral tablet form.

---

Official Administration and Dosage

Property	Administration Instruction
Routes	Intramuscular (IM), Intravenous (IV), and Oral (film-coated tablets).
Dosing Frequency	The oral dose is typically 125 to 250 mg administered three times a day (TID). Parenteral dosing may range from 1 to 4 times a day.
Maximum Dose	The maximum recommended daily dose for the oral form is 750 mg. The maximum daily parenteral dose is 1200 mg.
Pediatric Use	Approved for use in children 6 years of age and older, with a specific dose of 125 mg twice a day for a 6-week course.

---

Procedural Conditions and Duration

Treatment is administered in structured courses, and the use of the parenteral form (IV/IM) often lasts 10 to 14 days before the transition to oral tablets for continuation. Oral courses typically extend from 2 to 8 weeks.

For intravenous administration, the solution must be diluted in 100–150 ml of either 0.9% sodium chloride or 5% dextrose solution and infused slowly over 30–90 minutes. When treatment is completed, the dosage must be gradually reduced over a period of 2 to 3 days to ensure proper cessation of therapy. Use is contraindicated in the presence of acute liver or kidney dysfunction.

---

Research Evidence / Overview of Studies for Церекард

---

Evidence for Use in Acute Ischemic Stroke and Recovery

Research has primarily studied Церекард in large, randomized, double-blind trials conducted during the acute and early recovery periods following an ischemic stroke of moderate severity. These studies, such as the MIR trial, assessed changes in functional status using standardized instruments like the Modified Rankin Scale (mRS), and patterns observed in neurological measures using the National Institutes of Health Stroke Scale (NIHSS). Findings describe patterns observed in these measurements over the intermediate term, often up to 90 days. The evidence is closely associated with regional regulatory requirements and is based on studies primarily conducted within specific geographical areas.

---

Evidence for Chronic Brain Circulation Disorders (Dyscirculatory Encephalopathy)

Studies have focused on the use of Церекард in individuals with chronic cerebral ischemia (CCI), often involving older adults with existing comorbidities. The research examined outcomes related to cognitive status, mood state, and symptoms of persistent mental fatigue (asthenia). Studies monitored patient-reported experiences and provided insight into short-term changes during sequential treatment regimens. Long-term outcomes are not well characterized, as follow-up durations were often limited to two or three months, and data quality varies across studies utilizing subjective symptom scales.

---

What is Still Uncertain About Церекард's Research Landscape

Across all indications, long-term effects are not fully established, as follow-up durations were constrained in key studies. This lack of long-term data indicates that the durability of any reported patterns is not fully understood. Comparative evidence is lacking for how this medicine was observed against internationally recognized standard-of-care treatments for conditions like acute stroke. Furthermore, data for special populations, such as children, pregnant individuals, or those with rare comorbidities, remain insufficient, and research cannot predict individual outcomes for these groups.

Key Studies & References

1. Efficacy and Safety of Different Dosages of Mexidol® in Patients With Primary Open-angle Glaucoma (POAG) (NCT06903156)

Common questions about Церекард (FAQ)

---

Q: How long must one take Церекард to see an effect?

Official information indicates that this medicine is typically administered in structured courses, with oral therapy often lasting between 2 to 8 weeks. Clinical assessment focuses on functional status changes monitored over the full duration of the prescribed course, rather than focusing on the onset of immediate effects.

Q: What are the most common side effects of Церекард?

Regulatory documents state that the majority of documented adverse reactions are categorized as 'very rare', occurring in fewer than 1 in 10,000 patients. These very rare effects include symptoms like dry mouth, nausea, headache, and drowsiness.

Q: Is there dependence or withdrawal syndrome with Церекард?

The official product instructions mandate that the dosage be reduced gradually over a period of 2 to 3 days when a treatment course is concluded. This procedure is described in the official instructions to facilitate the cessation of therapy.

Q: Can Церекард be taken just for 'prevention'?

According to the official product information, the medicine is approved for the treatment of defined conditions, specifically those related to acute and chronic circulatory challenges. The regulatory indications do not include general preventative or prophylactic use for healthy individuals.

Q: Why does the instruction say that Церекард cannot be used in children?

Official regulatory documentation states that the use of this medicine is contraindicated (not allowed) in children up to 6 years of age due to insufficient data to guarantee safety in this young population. However, it is important to note that for certain specific approved conditions, the medicine may be used in children aged 6 years and older.

Q: If Церекард causes drowsiness, is that normal?

Drowsiness is listed as a documented, but very rare, side effect in the product information. Caution is officially advised when performing tasks that require quick psychophysical reactions, such as driving or operating machinery, due to the potential for drowsiness.

Q: How does Церекард differ from other drugs for improving circulation?

The drug is chemically unique because it combines an antioxidant structure (3-hydroxypyridine) with a metabolic component (succinate). Regulatory descriptions indicate that this dual structure is associated with a multimodal action intended to support cellular energy pathways and stabilize cell membranes.

Q: How does Церекард affect the ability to concentrate?

Studies focusing on patients with chronic brain circulation disorders observed that the medicine demonstrated a nootropic effect (related to brain function) and was linked to observed improvements in cognitive status and concentration for patients in the trial groups.

Q: How does Церекард affect blood vessels?

The medicine is primarily classified as a neuroprotective agent. While it is used for circulatory challenges, its succinate component is linked in research to signaling pathways that can influence processes like tissue vascularization (blood vessel formation) and overall cell metabolism.

Q: Is it necessary to undergo an examination before starting Церекард?

Official instructions strictly contraindicate the use of the medicine if a patient is experiencing acute liver or kidney dysfunction. This contraindication dictates that an assessment for these conditions is necessary prior to or during treatment to ensure the patient meets the established eligibility requirements.

Q: Is it true that Церекард helps with dizziness?

The medicine is officially indicated for the treatment of underlying conditions such as chronic cerebral ischemia (CCI). Since dizziness is often a symptom associated with CCI, the drug is used in the management of the primary condition for which it is approved.

The storage and disposal of Церекард (Ethylmethylhydroxypyridine Succinate) must strictly follow the official regulatory guidelines. Environmental conditions are controlled by a mandatory storage temperature that must not exceed 25°C. The medicine must also be kept protected from light and moisture.

Handling and Stability

The product must always be stored in its original packaging. A key constraint for the injection solution is that an opened ampoule is not recommended to be stored and must not be used later. Do not use the medicine past its labeled shelf life.

Disposal and Safety

All unused or expired Церекард must be kept out of the sight and reach of children. Disposal must be conducted according to specific official regulatory precautions and local requirements, meaning it should not be discarded in general household waste.